Search

922 Result(s)
Sort by

collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Retinal Health

Retinal Health

Human Pharma Clinical Pipeline Retinal Health therapeutic area
Digital solutions save lives

Digital solutions save lives

Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
How fast can a cheetah run wild and free?

How fast can a cheetah run wild and free?

Cheetahs’ top speed can reach up to 120km/h. But habitat loss, illegal wildlife trade and hunting made these impressive animals critically endangered.
Oncology

Oncology

Human Pharma Clinical Pipeline Oncology therapeutic area
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Award winning employer

Award winning employer

Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".